Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Fabio Casciani, Maxwell T. Trudeau, Horacio J. Asbun, Chad G. Ball, Claudio Bassi, Stephen W. Behrman, Adam C. Berger, Mark P. Bloomston, Mark P. Callery, John D. Christein, Massimo Falconi, Carlos Fernandez-del Castillo, Mary E. Dillhoff, Euan J. Dickson, Elijah Dixon, William E. Fisher, Michael G. House, Steven J. Hughes, Tara S. Kent, John W. Kunstman, Giuseppe Malleo, Stefano Partelli, Christopher L. Wolfgang, Amer H. Zureikat, Charles M. Vollmer, George Van Buren, Wande B. Pratt, Ammara A. Watkins, Joal D. Beane, Ammar A. Javed, Katherine E. Poruk, Kevin C. Soares, Vicente Valero, Zhi V. Fong, John A. Stauffer, Mary E. Dilhoff, Ericka N. Haverick, Carl R. Schmidt, Robert H. Hollis, Jeffrey A. Drebin, Brett Ecker, Russell Lewis, Matthew McMillan, Benjamin Miller, Priya Puri, Thomas Seykora, Michael J. Sprys, Stacy J. Kowalsky, Laura Maggino, Roberto Salvia, Giulia Savegnago, Lorenzo Cinelli, Nigel B. Jamieson, Lavanniya K.P. Velu, Ronald R. Salem
Publikováno v:
Surgery. 170:1195-1204
Background: The association between intraoperative estimated blood loss and outcomes after pancreatoduodenectomy has, thus far, been rarely explored. Methods: In total, 7,706 pancreatoduodenectomies performed at 18 international institutions composin
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Sidrah Khan, Caroline J. Rieser, Richard S. Hoehn, Samer Tohme, Ibrahim Nassour, David S. Medich, Amer H. Zureikat, Lindsay M. Sabik, Katherine Hrebinko
Publikováno v:
J Surg Res
Background Safety-net hospitals serve a vital role in society by providing care for vulnerable populations. Existing data regarding oncologic outcomes of patients with colon cancer treated at safety-net hospitals are limited and variable. The objecti
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Henry A. Pitt, Mohamed A. Adam, Amblessed E. Onuma, Joal D. Beane, Amer H. Zureikat, Andrew Billderback, Jeffrey D. Borrebach
Publikováno v:
The American Journal of Surgery. 222:29-34
The aim of this analysis is to compare the postoperative outcomes of resection and enucleation of small pancreatic neuroendocrine tumors (PNETs).The 2014-17 American College of Surgeons-NSQIP dataset was queried. Patients undergoing pancreatoduodenec
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Ibrahim Nassour, Kenneth K. Lee, Samer Tohme, Christof Kaltenmeier, Sidrah Khan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Richard S. Hoehn, Katherine Hrebinko
Publikováno v:
Pancreas
Objectives The objective of this study was to create a composite measure, optimal oncologic surgery (OOS), for patients undergoing distal pancreatectomy for pancreatic adenocarcinoma and identify factors associated with OOS. Methods Adult patients un
Autor:
M.E. Hogg, Brian A. Boone, Kenneth K. Lee, Alessandro Paniccia, Nathan Bahary, Susannah G. Ellsworth, Amer H. Zureikat, Joal D. Beane, David L. Bartlett, Asmita Chopra, Michael T. Lotze, Aatur D. Singhi, Herbert J. Zeh, Adam C. Olson, Jacob C. Hodges, Steve Burton
Publikováno v:
Ann Surg Oncol
BACKGROUND. Neoadjuvant therapy is increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC). It is unknown whether neoadjuvant chemoradiotherapy is more effective than chemotherapy (NCRT vs. NAC). We aim to compare pathological and
Autor:
Maxwell T. Trudeau, Fabio Casciani, Brett L. Ecker, Laura Maggino, Thomas F. Seykora, Priya Puri, Matthew T. McMillan, Benjamin Miller, Wande B. Pratt, Horacio J. Asbun, Chad G. Ball, Claudio Bassi, Stephen W. Behrman, Adam C. Berger, Mark P. Bloomston, Mark P. Callery, Carlos Fernandez-del Castillo, John D. Christein, Mary E. Dillhoff, Euan J. Dickson, Elijah Dixon, William E. Fisher, Michael G. House, Steven J. Hughes, Tara S. Kent, Giuseppe Malleo, Ronald R. Salem, Christopher L. Wolfgang, Amer H. Zureikat, Charles M. Vollmer
This study aims to present a full spectrum of individual patient presentations of pancreatic fistula risk, and to define the utility of mitigation strategies amongst some of the most prevalent, and vulnerable scenarios surgeons encounter.The FRS has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e4438f83dfe6550d15ddf10ccc735a
https://hdl.handle.net/11562/1086003
https://hdl.handle.net/11562/1086003
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify